Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor... see more

Recent & Breaking News (OTCQB:NWBO)

EARLY POSITIVE RESPONSES SEEN IN OVER 50% OF DCVAX®-DIRECT PATIENTS TO DATE

PR Newswire May 27, 2014

NW BIO ANNOUNCES FIRST DATA FROM ONGOING DCVAX-DIRECT TRIAL

PR Newswire May 15, 2014

PRESENTATION ON NW BIO'S DCVAX-DIRECT TRIAL ANNOUNCED FOR ASCO ANNUAL MEETING

PR Newswire April 22, 2014

NW BIO CLOSES ON FIRST $15 MILLION OF FINANCING FOR SUBSTANTIAL EXPANSION OF EUROPEAN PRODUCTION CAPACITY

PR Newswire April 15, 2014

NW BIO ANNOUNCES FINANCING OF UP TO $32 MILLION

PR Newswire April 10, 2014

NW BIO AGAIN SETS FEUERSTEIN RECORD STRAIGHT

PR Newswire April 7, 2014

NW BIO REFUTES FURTHER FALSE AND MISLEADING CLAIMS BY FEUERSTEIN

PR Newswire March 28, 2014

Northwest Biotherapeutics To Present At The 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference

PR Newswire March 27, 2014

NW Bio Refutes False Claims By Adam Feuerstein

PR Newswire March 12, 2014

NW Bio Announces Two German Approvals: "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement

PR Newswire March 10, 2014

NW Bio Receives Recommendation To Continue With Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Board's Safety Review

PR Newswire March 7, 2014

NW Bio to Present at BIO CEO and Investor Conference 2014

PR Newswire February 6, 2014

NW Bio Enters Into Agreements For Large-Scale Expansion Of Product Manufacturing, Handling And Distribution

PR Newswire January 27, 2014

NW Bio to Present at Phacilitate's Washington Bioleaders' Immunotherapy 2014 Forum

PR Newswire January 27, 2014

NW Bio To Present At Biotech Showcase 2014

PR Newswire January 9, 2014

NW Bio's International Phase III GBM Brain Trial Is Subject Of BBC TV Report In The UK

PR Newswire December 30, 2013

NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sector's Recent Market Decline

PR Newswire December 16, 2013

First Interim Analysis Of NW Bio's Phase III GBM Trial Triggered By Reaching Required Number Of "Events"

PR Newswire December 10, 2013

Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013

PR Newswire December 5, 2013

Northwest Biotherapeutics Completes Public Offering Of Common Stock And Warrants; Underwriter Exercises Full Over-Allotment

PR Newswire November 25, 2013